Grupo Trasplante INC

𝗛𝗮𝗽𝗽𝗲𝗻𝗶𝗻𝗴 𝗧𝗢𝗗𝗔𝗬 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗳𝗼𝗿 𝗙𝗥𝗘𝗘 @Florent_Malard @nagler_EBMT @AnnalisaRugger1 @BipinSavani @Mohty_EBMT @sanofi @TheEBMT

We recently caught up with the wonderful @AnnaSureda5 to gain valuable insight into the EBMT Consensus on autologous and allogeneic transplantation in classical #HodgkinLymphoma.🩸 Watch the interview here: 🎥 👉 ow.ly/vuUM50YzKUY #LYMsm #Lymphoma #BMTsm #EBMT26 #HemOnc @TheEBMT

Feliz Semana Santa y nos vemos en Córdoba en 3 semanas! 1. Si participas del GT TerAvan/CART, aprovecha las 2 plazas por programa CART financiadas por @GETH_info 2. Adicionalmente, inscripciones en app.bipeek.com/registro-event… + detalles en …th-tc-portal-rxyi17ci.sites.blink.new/profesionales/… #CARtingToGETHer

⭐ GvHD Hub spotlight ⭐ Explore our overview of an ad hoc analysis of the phase II ROCKstar trial, summarizing response dynamics to belumosudil in patients with #cGvHD. Learn more: bit.ly/3PEZGt4 #GvHD #GvHDsm #MedEd #MedNews

Management strategies in infections by multidrug-resistant bacteria, WP Infections in transplant #EBMT26

CONGRESS | The GvHD Hub covered the latest updates and key presentations in #GvHD from #EBMT26. Catch up with our live coverage! 👉Chronic GvHD: bit.ly/4swbCvL 👉Acute GvHD: bit.ly/4rVuTpe 👉GvHD prophylaxis: bit.ly/4lyVG9v #GvHDsm #MedEd #MedicalCongress @TheEBMT

New publication 📝 Results from the final analysis of REACH5, published in @Haematologica, show the BOR rate was 84.4% in pediatric patients with #cGvHD after 36 months of follow-up. Learn more: bit.ly/3Pej7si #GvHD #GvHDsm #MedNews #MedEd

As #EBMT26 comes to an end… 📍 Next stop: Rotterdam. #EBMT27 “Bridging Scientific Research and Clinical Reality.” 🌍 See you in 2027

@N_Polverelli Talks about myeloproliferative transplantation and neoplasia, current recommendations by EBMT #MPN #EBMT26

CONGRESS | #EBMT26 | PRESENTATION Udo Holtick reports updated findings from a multicenter retrospective analysis of a German-Austrian cohort of patients with #cGvHD who received belumosudil via a managed-access program (N = 144). The best objective response rate was 60% (CR, 6%; PR, 54%) and responses were observed across all organ systems. Median TTR was 3.1 months. One-year FFS and OS were 68.0% and 90.7%, respectively. Treatment-emergent adverse reactions (CTCAE Grade 3–4) were mostly infectious events. Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #GvHD #GvHDsm #MedNews #MedEd @TheEBMT @UniCologne

CML Indications - Transplant #EBMT26

Nursing plays a fundamental role in the care of the transplanted patient, #nurses #EBMT26 @michellekenyon5 @TheEBMT_Nurses

Enfermería juega un rol Fundamental en el Cuidado del paciente trasplantado, #nurses #EBMT26 @michellekenyon5

@monicahemato talk about SOS/VOD in #EBMT26

Today - present 2 printed póster - EBMT 2026 ✅Early Ruxolitinib use in lung GVHD ✅Outcomes of Post-Transplant Patients Admitted to the ICU #EBMT26 #EBMTPOSTER #Younghematology @ContactoAmeh

EICH ocular es un fenómeno probablemente infraestimado, siendo considerado un órgano que posee compromiso mayor al reportado…. #GVHD #ocularGVHD

Pos HSCT and ICU (Poster B134) 🩸 -Mexico City – 16y (2009-2025) -1178 Px🙋 - ASCT n=600 and Allo-SCT n=578 -Principal Dx Acute Leukemia …. Low admission rate, but high mortality among those requiring ICU #EBMT26 #poster #hsct

This ASTCT guideline provides consensus recommendations for transplantation in classical Hodgkin lymphoma, including timing of auto-HCT, integration of novel agents and the role of #alloHCT in relapsed or refractory disease. astctjournal.org/article/S2666-…

EBMT 2026